自身抗体在自身免疫性肝病中的预测价值

王嘉森; 姚定康

自身抗体在自身免疫性肝病中的预测价值

第二军医大学附属长征医院内科

基金项目:

国家自然科学基金(C03030204)；

详细信息

中图分类号: R575
计量
- 文章访问数: 4251
- HTML全文浏览量: 15
- PDF下载量: 1220
- 被引次数: 0
出版历程
- 出版日期: 2011-03-20

Value of autoantibodies in predicting autoimmune liver disease

Research funding:

摘要

摘要: 自身抗体作为自身免疫性肝病的诊断标志物已经在临床上得到了广泛应用,但其在病情严重程度及预后判断方面的价值报道并不多,事实上某些自身抗体除本身的诊断价值外,还具有预测病情的作用:如抗可溶性肝抗原抗体、抗肌动蛋白抗体、抗肝细胞溶质抗原Ⅰ型抗体、抗去唾液酸糖蛋白受体抗体、抗染色体抗体、抗环瓜氨酸多肽抗体和抗肝肾微粒体Ⅲ型抗体与自身免疫性肝炎的发生、发展及恶化有一定的相关性,其中抗可溶性肝抗原抗体与某些自身免疫性肝炎患者严重肝组织学改变、长期维持治疗、停药后再度恶化以及肝衰竭的发生相关;抗gp210抗体、抗Sp100抗体和抗着丝点抗体在原发性胆汁性肝硬化中有一定的预测意义,其中抗gp210抗体可提示原发性胆汁性肝硬化患者有较严重的界面性肝炎、小叶炎症以及易进展为肝衰竭等。
- 自身抗体 /
- 肝炎,自身免疫
Abstract: Autoantibodies have been widely used in autoimmune liver disease as diagnostic markers, but the value of estimating disease severity and prognosis has not been commonly comprehended.Actually, autoantibodies are valuable in predicting disease severity and treatment outcome as well as directing the diagnosis.Antibodies to soluble liver antigen, actin, liver cytosol type 1, asialoglycoprotein receptor, chromatin, cyclic citrullinated peptide, and uridine glucuronosyltransferases have been considered to be associated with the occurrence, severity and progression of autoimmune hepatitis.For example, antibody to soluble liver antigen is associated with severe histological changes, long durations of treatment, relapse after drug withdrawal and high frequency of liver failure.Besides, antibodies to Sp100, gp210 and centromere have prognostic value in primary biliary cirrhosis, for instance, antibody to gp210 is associated with severe interface hepatitis, lobular inflammation, and progression to liver failure.
- autoantibodies /
- hepatitis

HTML全文

参考文献(25)

[1]Luth S, Herkel J, Kanzler S, et al.Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis[J].J Clin Gastroenterol, 2008, 42 (8) :926-930.

[2]Torres-Collado AX, Czaja AJ, Gelpi C.Anti-tRNP (ser) sec/SLA/LP autoantibodies.Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs[J].Liver Int, 2005, 25 (2) :410-419.

[3]Klein R, Berg PA.Significance of antibodies to soluble liver/liver pancreas antigen:experiences in Germany[J].Liver Int, 2010, 30 (1) :155-156.

[4]Czaja AJ, Donaldson PT, Lohse AW.Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis[J].Am J Gastroenterol, 2002, 97 (2) :413-419.

[5]Ma Y, Okamoto M, Thomas MG, et al.Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease[J].Hepatology, 2002, 35 (3) :658-664.

[6]Gueguen P, Dalekos G, Nousbaum JB, et al.Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1[J].J Clin Immunol, 2006, 26 (6) :495-505.

[7]Bridoux-Henno L, Maggiore G, Johanet C, et al.Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody[J].Clin Gastroenterol Hepatol, 2004, 2 (9) :825-830.

[8]Beland K, Lapierre P, Marceau G, et al.Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection[J].J Autoimmun, 2004, 22 (2) :159-166.

[9]Kakegawa T, Ise H, Sugihara N, et al.Soluble asialoglycoprotein receptors reflect the apoptosis of hepatocytes[J].Cell Transplant, 2002, 11 (5) :407-415.J Clini Hepatol, March 2011, Vol.27, No.3

[10]Hausdorf G, Roggenbuck D, Feist E, et al.Autoanti-bodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA--revival of a disease-activity marker in autoimmune hepatitis[J].Clin Chim Acta, 2009, 408 (1-2) :19-24.

[11]El-Din Elshazly LB, Youssef AM, Mahmoud NH, et al.Study of nonstandard auto-antibodies as prognostic markers in auto immune hepatitis in children[J].Ital J Pediatr, 2009, 35 (1) :22.

[12]Czaja AJ, Shums Z, Norman GL.Nonstandard antibodies as prognostic markers in autoimmune hepatitis[J].Autoimmunity, 2004, 37 (3) :195-201.

[13]Montano-Loza A, Czaja AJ, Carpenter HA, et al.Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis[J].Autoimmunity, 2006, 39 (4) :341-348.

[14]Czaja AJ.Autoimmune liver disease[J].Curr Opin Gastroenterol, 2007, 23 (3) :255-262.

[15]Csepregi A, Nemesánszky E, Luettig B, et al.LKM3 autoantibodies in hepatitis C cirrhosis:a further phenomenon of the HCV-induced autoimmunity[J].Am J Gastroenterol, 2001, 96 (3) :910-911.

[16]Dalekos GN, Makri E, Loges S, et al.Increased inci-dence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece[J].Eur J Gastroenterol Hepatol, 2002, 14 (1) :35-42.

[17]Muratori P, Muratori L, Gershwin ME, et al.'True'an-timitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?[J].Clin Exp Immunol, 2004, 135 (1) :154-158.

[18]Shimoda S, Nakamura M, Ishibashi H, et al.Molecular mim-icry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis[J].Gastroenterology, 2003, 124 (7) :1915-1925.

[19]Bogdanos DP, Baum H, Butler P, et al.Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection[J].Dig Liver Dis, 2003, 35 (11) :801-805.

[20]Nakamura M, Kondo H, Mori T, et al.Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology, 2007, 45 (1) :118-127.

[21]Muratori P, Muratori L, Ferrari R, et al.Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis[J].Am J Gastroenterol, 2003, 98 (2) :431-437.

[22]周晔, 蒋天舒, 陈燕等.自身抗原gp210融合蛋白的重组表达及其临床应用研究[J].中华实验诊断学, 2007, 11 (6) :739-743.

[23]Yang WH, Yu JH, Nakajima A, et al.Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure[J].Clin Gastroenterol Hepatol, 2004, 2 (12) :1116-1122.

[24]Assassi S, Fritzler MJ, Arnett FC, et al.Primary biliary cirrhosis (PBC) , PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients[J].J Rheumatol, 2009, 36 (10) :2250-2256.

[25]Lüth S, Herkel J, Kanzler S, et al.Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis[J].J Clin Gastroenterol, 2008, 42 (8) :926-930.

施引文献

资源附件(0)

访问统计